Claimable

Overview

Claimable is an AI-powered insurance denial appeals platform that generates and submits customized appeals at scale for patients, providers, pharma patient-support teams, hubs, and specialty pharmacies, with a reported 80%+ success rate. The company addresses a documented gap: an estimated 200M+ U.S. insurance claims are denied annually and fewer than 1% are appealed, even though roughly half of appeals succeed when filed.

Claimable is best read as an AI-native appeals engine, not a full ePA switch, a hub case-management platform, or a benefit-verification operations vendor. The relevant manufacturer wedge is denial-resolution speed and appeal-success rates for specialty, biologic, and high-rejection therapies.

Reimbursement and PA Capability Model

The framework below standardizes how Rx Almanac evaluates reimbursement-prior-auth capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Claimable is evaluated as an AI-native appeals engine, not a full ePA switch, a hub case-management platform, or a benefit-verification operations vendor.

Capability	Buyer should compare	Claimable readout
Electronic PA initiation and payer connectivity	ePA submission, payer integrations, plan-specific requirements, real-time decisioning, and transaction reach.	Adjacent. Claimable enters the workflow after denial, not at initial PA submission; expect a real-time dashboard across submitted appeals rather than an ePA transaction network.
Benefits verification and coverage discovery	Eligibility, pharmacy/medical benefit checks, policy criteria, coverage route, and reimbursement path identification.	Not the use case. Claimable acts on the denial signal; pair with a BV or coverage-discovery vendor for upstream eligibility work.
Clinical documentation and appeals support	Document collection, criteria matching, appeal packets, peer-to-peer prep, and denial management.	Core PA casework. AI generates customized appeal letters from clinical evidence, payer policy analysis, and precedent matching; submission via fax/mail.
Provider workflow integration	EHR, portal, fax, call, pharmacy, and practice-management workflows that reduce office burden.	Validate by workflow. Enterprise API targets pharma hubs and specialty pharmacies; confirm EHR/portal handoffs and how appeal status flows back to provider staff.
Automation, AI, and queue prioritization	AI agents, rules engines, form completion, status retrieval, queue triage, and exception handling.	Core automation workflow. AI agent drives the appeal-generation and submission workflow end to end.
Reporting, status visibility, and policy intelligence	Case status, payer trend reporting, denial reasons, turnaround metrics, and policy-change intelligence.	Core reporting layer. Strategic denial analytics and outcome tracking dashboard surface denial drivers, success rates, and turnaround.

Buyer Fit

• Evaluation trigger: Include Claimable when denial volume and appeal turnaround are the bottleneck, not initial PA submission or BV operations.
• Best-fit buyers: Pharma patient-support teams, hubs, specialty pharmacies, providers, and health systems running specialty, biologic, or small-molecule programs with material denial rates across Immunology/Autoimmune, Neurology, Respiratory, Endocrinology/Diabetes, Oncology, and Cardiology.
• Less ideal fit: Programs where the primary need is ePA submission, BV, hub case management, fulfillment, or nurse-led patient engagement.
• Commercial fit: Per-transaction pricing; scope appeal types, payer reach, clinical-review boundaries, and SLA expectations in the SOW.
• Award diligence: Confirm payer reach, clinical-review boundaries, appeal-type depth (medical necessity, formulary exception, step therapy), human-in-the-loop oversight, and whether the platform is payer-side, provider-side, hub-side, or manufacturer-side in each engagement.

Differentiators

• 80%+ appeal success rate: Claimable reports a roughly 80% success rate with resolutions often under 10 days, against a typical 30-60 day manual appeals cycle.
• Resolutions in under 10 days: Faster turnaround compresses time-to-therapy on denied claims and reduces abandonment risk.
• Enterprise API for hubs and specialty pharmacies: API-led integration targets pharma hub and specialty-pharmacy workflows, not just direct-to-patient submissions.
• Strategic denial analytics: The outcome dashboard surfaces denial drivers, success rates, and turnaround by payer and treatment for manufacturer access teams.
• External recognition: 2026 Fierce 15 honoree, Fast Company 2025 World Changing Ideas Awards, WSJ feature, and NVIDIA Inception participation provide third-party signal for a sub-10-person startup.

RFP Questions

• Which payer plans and appeal types (medical necessity, formulary exception, step therapy, prior authorization) are live for the product’s expected patient mix?
• What clinical evidence sources, payer policy databases, and precedent libraries feed the AI appeal generator?
• How are denials triaged, prioritized, and routed back to provider, hub, or specialty-pharmacy staff?
• What human review, clinician oversight, transcript QA, and audit trails are included before submission?
• What success-rate, turnaround, and denial-driver reporting can the manufacturer receive without crossing patient or payer compliance boundaries?
• How does the platform integrate with hub case management, specialty pharmacy, EHR, and manufacturer data warehouses?

Recent Activity

• 2026-05 - Current Claimable For Pharma materials emphasize 85+ medications, therapy lanes, hub / SP / API integration, payer / state / therapy denial analytics, and fast-launch claims that require validation.

• 2026 - Named to Fierce 15 list; recognition stack also includes Fast Company 2025 World Changing Ideas Awards and NVIDIA Inception Program.

• 2025-03 - CEO on AI panel at HIMSS25, raising profile with health-system buyers.

• 2025-02 - WSJ feature covering patient wins against UnitedHealthcare using Claimable.

• 2024-10 - AI appeals engine launched with coverage for 60+ treatments; reported 1.6x success rate versus manual appeals.

• 2024-09 - Platform launch.